Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma
Abroad (travel likely)RecruitingPHASE2
Conditions
Melanoma · Immune-related Adverse Event · Immune Checkpoint Inhibitor
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Sun yat-sen uniersity, Guangzhou, Guangdong, China
Nanshan hospital, Shenzhen, Guangdong, China
Contact: Study coordinator (qiming zhou, phD)
Study leads
Xiaoshi Zhang, phD
Study Director
Penghui Zhou, PhD
Principal Investigator
Ya Ding, PhD
Principal Investigator
Dandan Li, PhD
Principal Investigator
Jingjing Zhao, PhD
Principal Investigator